Home » Stocks » ATHA

Athira Pharma, Inc. (ATHA)

Stock Price: $22.04 USD 1.98 (9.87%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Pre-market: $22.00 -0.04 (-0.18%) Jan 26, 7:06 AM
Market Cap 651.65M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 7.56M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $22.04
Previous Close $20.06
Change ($) 1.98
Change (%) 9.87%
Day's Open 20.24
Day's Range 20.06 - 22.14
Day's Volume 753,905
52-Week Range 16.02 - 34.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 4 days ago

The clinical-stage biopharma company announced the pricing of a public stock offering.

GlobeNewsWire - 5 days ago

BOTHELL, Wash., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to resto...

GlobeNewsWire - 6 days ago

BOTHELL, Wash., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to resto...

Seeking Alpha - 2 weeks ago

Athira is a recent IPO with early but interesting data in AD. They will provide data from a potentially pivotal phase 2/3 trial in end-2022.

GlobeNewsWire - 2 weeks ago

SEATTLE, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health ...

GlobeNewsWire - 1 month ago

SEATTLE, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health ...

GeekWire - 1 month ago

Seattle-based biotech company Athira Pharma announced a three-year grant totaling $15 million from the National Institute on Aging to support an upcoming clinical trial of a treatment that see...

GlobeNewsWire - 1 month ago

SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health ...

GlobeNewsWire - 1 month ago

SEATTLE, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health ...

GlobeNewsWire - 2 months ago

 - LIFT-AD clinical trial evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer's disease, actively enrolling 

GlobeNewsWire - 2 months ago

SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health ...

GlobeNewsWire - 3 months ago

- Expert neuropsych iatric clinician to discuss the testing method and its correlation to clinical results

PRNewsWire - 3 months ago

SEATTLE, Oct. 8, 2020 /PRNewswire/ -- Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the appointment of M...

GlobeNewsWire - 3 months ago

- Study to evaluate the safety and efficacy of ATH-1017 to improve mild-to- moderate Alzheimer’s disease -

GuruFocus - 3 months ago

Andreas Halvorsen (Trades, Portfolio)'s Viking Global Investors recently participated in the initial public offering of biotech company Athira Pharma Inc. (NASDAQ:ATHA). According to GuruFocus...

GlobeNewsWire - 4 months ago

SEATTLE, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore n...

GeekWire - 4 months ago

More than 5 million Americans have Alzheimer’s disease, and the number is projected to rise to nearly 14 million by 2050.

Market Watch - 4 months ago

Shares of Athira Pharma Inc. ATHA, +5.48% rallied in their public debut, as the first trade was 17.4% above the initial public offering price.

Market Watch - 4 months ago

Athira Pharma Inc. ATHA, priced its initial public offering at $17 a share, the top end of its proposed price range.

Benzinga - 4 months ago

Athira Pharma Inc. (NASDAQ: ATHA) on Thursday upsized its initial public offering plans over what it earlier reported in a filing with the Securities and Exchange Commission.

GeekWire - 4 months ago

Athira Pharma will raise at least $204 million as the Seattle biotech startup becomes a public company on Friday.

GlobeNewsWire - 4 months ago

SEATTLE, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore n...

About ATHA

Athira Pharma, a clinical-stage biopharmaceutical company, develops small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in various clinical trials for the treatment of Alzheimer's and Parkinson's diseases. The company also develops product candidates, which are in preclinical stage, including ATH-1019 for depression; and ATH-1018 for peripheral neuropathy. Athira Pharma, Inc. was formerly known as M3 ... [Read more...]

Industry
Biotechnology
IPO Date
Sep 18, 2020
CEO
Dr. Leen Kawas
Employees
15
Stock Exchange
NASDAQ
Ticker Symbol
ATHA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Athira Pharma stock is "Buy." The 12-month stock price forecast is 44.25, which is an increase of 100.77% from the latest price.

Price Target
$44.25
(100.77% upside)
Analyst Consensus: Buy